BRAF-V600E
Showing 1 - 25 of 2,986
Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive
Not yet recruiting
- Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
- Non-investigational
- (no location specified)
May 11, 2023
Aspirin in Combination With Trametinib and Dabrafenib
Not yet recruiting
- NSCLC
- +4 more
- Combind asprin with Trametinib and Dabrafenib
- (no location specified)
Aug 4, 2023
Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy
Not yet recruiting
- Colorectal Cancer Metastatic
- Tunlametinib plus Vemurafenib
- Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
- (no location specified)
Aug 15, 2023
Non Small Cell Lung Cancer Trial (HLX208+HLX10)
Not yet recruiting
- Non Small Cell Lung Cancer
- HLX208+HLX10
- (no location specified)
Nov 30, 2022
Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)
Not yet recruiting
- Colorectal Cancer
- BRAF V600E Mutation Positive
- Encorafenib Oral Capsule + Cetuximab
- (no location specified)
Jan 30, 2023
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)
Completed
- BRAF V600E Unresectable or Metastatic Melanoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 9, 2022
Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)
Not yet recruiting
- Non-small-cell Lung Cancer
- (no location specified)
Jun 8, 2023
BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer
Recruiting
- Metastatic Non-small Cell Lung Cancer
- BRAF V600 Mutation
-
Lyon, Rhône Alpes, FranceCHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
Sep 14, 2022
Metastatic Colorectal Cancer, mCRC Trial in Shenyang (HLX208)
Recruiting
- Metastatic Colorectal Cancer
- mCRC
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital
May 1, 2022
Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)
Recruiting
- Colorectal Cancer
- VIC
- Bevacizumab Plus Chemotherapy
-
Shanghai, ChinaDepartment of General Surgery, Zhongshan Hospital, Fudan Univers
Sep 14, 2022
CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])
Recruiting
- CRC
- HLX208
- Cetuximab Injection [Erbitux]
-
Shanghai, ChinaFudan University Affiliated Oncology Hospital
Dec 30, 2021
Liquid Biopsy, Melanoma (Skin), Melanoma Stage III Trial in Rome (Affinity Mediated Transport Amplification (AMT))
Recruiting
- Liquid Biopsy
- +4 more
- Affinity Mediated Transport Amplification (AMT)
-
Rome, Italy"Regina Elena" National Cancer Institute
Jul 13, 2023
Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH Trial in Beijing (HLX208)
Recruiting
- Langerhans Cell Histiocytosis
- +3 more
-
Beijing, ChinaPeking Union Medical College Hospital
Dec 30, 2021
Solid Tumor Trial in Guangzhou (HLX 208)
Recruiting
- Solid Tumor
- HLX 208
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Jan 26, 2022
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)
Active, not recruiting
- BRAF NP_004324.2:p.V600X
- +6 more
- Cetuximab
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago
Recruiting
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
- +2 more
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
-
Chicago, IllinoisNorthwestern University
Nov 16, 2022
NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)
Not yet recruiting
- Non-small Cell Lung Cancer
- +32 more
- (no location specified)
Mar 30, 2023
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,
Not yet recruiting
- Colon Adenocarcinoma
- +4 more
- Encorafenib
- +5 more
- (no location specified)
Jan 24, 2023
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,
Recruiting
- BRAF NP_004324.2:p.V600M
- +6 more
- Binimetinib
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Aug 17, 2022
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Active, not recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Dabrafenib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)
Recruiting
- Anaplastic Thyroid Cancer
- ATC
-
Shanghai, ChinaFudan University Affiliated Oncology Hospital
Dec 30, 2021
NSCLC Trial in China (Dabrafenib, Trametinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Harbin, Heilongjiang, China
- +9 more
Jun 13, 2022